Aurobindo Pharma completes acquisition of US-listed generic pharmaceuticals company Lannett

M&A / JV 30 Jun 2026 · Completed· ✓ Verified

Aurobindo Pharma Limited, a major Indian generic pharmaceutical manufacturer, completed the acquisition of Lannett Company Inc., a US-listed producer of generic and branded pharmaceuticals, through its wholly owned US subsidiary Aurobindo Pharma USA Inc. The completion intimation was filed with the NSE on 30 June 2026. This deal represents a significant cross-border consolidation in the generic pharmaceuticals sector, expanding Aurobindo's US market footprint. The acquisition structure-use of a wholly owned subsidiary as the acquisition vehicle-is standard for foreign investor protection under US securities law and Indian FEMA compliance.

Why it mattersCross-border pharma M&A via a subsidiary structure triggers simultaneous compliance with Indian foreign investment rules (FEMA), US securities law (SEC/Hart-Scott-Rodino), and target delisting procedures-a complex tripartite gating sequence that defines deal closure in this cohort.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals